Esperion Therapeutics Inc (ESPR) support and resistance · rev $332.3M
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page maps Esperion Therapeutics Inc (ESPR) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
ESPR currently screens at market cap $816.9M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ESPR 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ESPR quote page for the session range and the stock page for the full model.
Not investment advice.